Abstract:Recent advances in computational methods provide the promise of dramatically accelerating drug discovery. While mathematical modeling and machine learning have become vital in predicting drug-target interactions and properties, there is untapped potential in computational drug discovery due to the vast and complex chemical space. This paper builds on our recently published computational fragment-based drug discovery (FBDD) method called fragment databases from screened ligand drug discovery (FDSL-DD). FDSL-DD uses in silico screening to identify ligands from a vast library, fragmenting them while attaching specific attributes based on predicted binding affinity and interaction with the target subdomain. In this paper, we further propose a two-stage optimization method that utilizes the information from prescreening to optimize computational ligand synthesis. We hypothesize that using prescreening information for optimization shrinks the search space and focuses on promising regions, thereby improving the optimization for candidate ligands. The first optimization stage assembles these fragments into larger compounds using genetic algorithms, followed by a second stage of iterative refinement to produce compounds with enhanced bioactivity. To demonstrate broad applicability, the methodology is demonstrated on three diverse protein targets found in human solid cancers, bacterial antimicrobial resistance, and the SARS-CoV-2 virus. Combined, the proposed FDSL-DD and a two-stage optimization approach yield high-affinity ligand candidates more efficiently than other state-of-the-art computational FBDD methods. We further show that a multiobjective optimization method accounting for drug-likeness can still produce potential candidate ligands with a high binding affinity. Overall, the results demonstrate that integrating detailed chemical information with a constrained search framework can markedly optimize the initial drug discovery process, offering a more precise and efficient route to developing new therapeutics.

An adapted consensus protein design strategy for identifying globally optimal biotherapeutics

Streamlining Computational Fragment-Based Drug Discovery Through Evolutionary Optimization Informed by Ligand-Based Virtual Prescreening

Design of High Affinity Binders to Convex Protein Target Sites

De Novo Design of Peptide Binders to Conformationally Diverse Targets with Contrastive Language Modeling

Robust de novo design of protein binding proteins from target structural information alone

Massively Parallel De Novo Protein Design for Targeted Therapeutics.

De novo design of high-affinity protein binders with AlphaProteo

De novo design of drug-binding proteins with predictable binding energy and specificity

IgDesign: In vitro validated antibody design against multiple therapeutic antigens using inverse folding

Improved protein binder design using ꞵ-pairing targeted RFdiffusion

Computational design of developable therapeutic antibodies: efficient traversal of binder landscapes and rescue of escape mutations

Design of Peptide Binders to Conformationally Diverse Targets with Contrastive Language Modeling

De novo design of high-affinity binders of bioactive helical peptides

Integrating Computational Design and Experimental Approaches for Next-Generation Biologics

Better Prior Distribution for Antibody Complementarity-Determining Regions Design

Drug Design and Repurposing with a Sequence-to-drug Paradigm

Consensus sequence design as a general strategy to create hyperstable, biologically active proteins

Protein CREATE enables closed-loop design of de novo synthetic protein binders

Partial Consensus Design and Enhancement of Protein Function by Secondary-Structure-Guided Consensus Mutations.

Automated optimisation of solubility and conformational stability of antibodies and proteins

A Novel Rational PROTACs Design and Validation via AI-Driven Drug Design Approach